uniQure Q2 2026: FDA Alignment on Accelerated Approval for Huntington's Gene Therapy, Cash Runway Extended to 2030
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure reported Q2 2026 financial results and announced FDA alignment on an accelerated approval pathway for its Huntington's disease gene therapy, AMT-130. The company's cash position of $810.3 million, bolstered by a recent $259 million offering, is expected to fund operations into 2030.
Key Events · Earnings and Guidance · QURE
-
FDA Alignment on Accelerated Approval
The FDA agreed that a BLA submission for AMT-130 under the accelerated approval pathway is reasonable based on existing clinical data. uniQure plans to submit the BLA in Q3 2026 and initiate a confirmatory study.
-
Cash Runway Extended to 2030
Following a $259 million upsized public offering in June 2026, uniQure held $810.3 million in cash and investments as of June 30, 2026, expected to fund operations into 2030.
-
Q2 2026 Net Loss Widens
Net loss was $81.1 million ($1.22 per share), compared to $37.7 million in Q2 2025, driven by a $16 million non-cash fair value loss on pre-funded warrants and unfavorable foreign currency movements.
-
Pipeline Progress Across Multiple Programs
Preliminary data from the AMT-260 Phase I/IIa trial in refractory MTLE showed early biological signals of therapeutic activity. New data from the AMT-191 Fabry disease program were also presented.
Analysis · QURE · Life Sciences
uniQure's Q2 2026 results mark a pivotal quarter. The FDA has aligned on an accelerated approval pathway for AMT-130 in Huntington's disease, with a BLA submission planned for Q3 2026. This regulatory clarity, combined with a strengthened balance sheet following a $259 million offering, extends the cash runway into 2030 and funds the anticipated commercial launch. The net loss widened to $81.1 million, driven by a $16 million non-cash fair value loss on pre-funded warrants and unfavorable foreign currency movements, but the core story is the de-risked regulatory path and pipeline momentum.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $38.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.